Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Leishmaniasis in humans: drug or vaccine therapy?
Leishmania is an obligate intracellular pathogen that invades phagocytic host cells.
Approximately 30 different species of Phlebotomine sand flies can transmit this parasite …
Approximately 30 different species of Phlebotomine sand flies can transmit this parasite …
Possibilities and challenges for develo** a successful vaccine for leishmaniasis
Leishmaniasis is a vector-borne disease caused by different species of protozoan parasites
of the genus Leishmania. It is a major health problem yet neglected tropical diseases, with …
of the genus Leishmania. It is a major health problem yet neglected tropical diseases, with …
A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH
M Osman, A Mistry, A Keding, R Gabe… - PLoS neglected …, 2017 - journals.plos.org
Background Visceral leishmaniasis (VL or kala azar) is the most serious form of human
leishmaniasis, responsible for over 20,000 deaths annually, and post kala azar dermal …
leishmaniasis, responsible for over 20,000 deaths annually, and post kala azar dermal …
Chemotherapeutics of visceral leishmaniasis: present and future developments
Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging
with few treatment options. Long duration of treatment and drug toxicity further limit the target …
with few treatment options. Long duration of treatment and drug toxicity further limit the target …
From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection
Introduction Leishmaniasis is a major public health problem and the second most lethal
parasitic disease in the world due to the lack of effective treatments and vaccines. Even …
parasitic disease in the world due to the lack of effective treatments and vaccines. Even …
Recent developments and future prospects in the treatment of visceral leishmaniasis
Limited therapeutic options in visceral leishmaniasis (VL) make the treatment of this
neglected disease very challenging. In addition to this, long treatment duration and toxic …
neglected disease very challenging. In addition to this, long treatment duration and toxic …
Cutaneous leishmaniasis situation analysis in the Islamic Republic of Iran in preparation for an elimination plan
Iran has invariably been under the growing public health threat of cutaneous leishmaniasis
(CL), a significant barrier to local development that hinders the prevention and control efforts …
(CL), a significant barrier to local development that hinders the prevention and control efforts …
Host–pathogen interaction in leishmaniasis: immune response and vaccination strategies
Leishmaniasis is a zoonotic and vector-borne infectious disease that is caused by the genus
Leishmania belonging to the trypanosomatid family. The protozoan parasite has a digenetic …
Leishmania belonging to the trypanosomatid family. The protozoan parasite has a digenetic …
Leishmaniasis: prevention, parasite detection and treatment
T Kobets, I Grekov, M Lipoldova - Current Medicinal Chemistry, 2012 - benthamdirect.com
Leishmaniasis remains a public health problem worldwide, affecting approximately 12
million people in 88 countries; 50 000 die of it each year. The disease is caused by …
million people in 88 countries; 50 000 die of it each year. The disease is caused by …
The development and clinical evaluation of second-generation leishmaniasis vaccines
MS Duthie, VS Raman, FM Piazza, SG Reed - Vaccine, 2012 - Elsevier
Infection with Leishmania parasites results in a range of clinical manifestations and
outcomes. Control of Leishmania parasite transmission is extremely difficult due to the large …
outcomes. Control of Leishmania parasite transmission is extremely difficult due to the large …